Innovative Medicine — D&A
Business Segments · D&AJohnson & Johnson Innovative Medicine — D&A decreased by 20.1% to $832.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.7%, from $932.00M to $832.00M. Over 2 years (FY 2022 to FY 2024), Innovative Medicine — D&A shows relatively stable performance with a -3.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may signal recent heavy capital investment or acquisitions, while a decrease could suggest aging assets or a shift toward asset-light operations.
Detailed definition
This represents the non-cash expense allocated to the Innovative Medicine segment for the wear and tear of tangible asse...
Peer comparison
Standard across pharmaceutical peers as part of segment-level operating expense reporting.
jnj_segment_innovative_medicine_depreciation_and_amortizationHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.01B | $1.01B | $1.01B | $1.01B | $961.75M | $961.75M | $961.75M | $961.75M | $1.01B | $850.00M | $932.00M | $967.00M | $884.00M | $1.04B | $832.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -4.5% | +0.0% | +0.0% | +0.0% | +5.1% | -15.9% | +9.6% | +3.8% | -8.6% | +17.8% | -20.1% |
| YoY Change | — | — | — | — | -4.5% | -4.5% | -4.5% | -4.5% | +5.1% | -11.6% | -3.1% | +0.5% | -12.6% | +22.5% | -10.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — d&a?
- Johnson & Johnson (JNJ) reported innovative medicine — d&a of $832.00M in Q3 2025.
- How has Johnson & Johnson's innovative medicine — d&a changed year-over-year?
- Johnson & Johnson's innovative medicine — d&a decreased by 10.7% year-over-year, from $932.00M to $832.00M.
- What is the long-term trend for Johnson & Johnson's innovative medicine — d&a?
- Over 2 years (2022 to 2024), Johnson & Johnson's innovative medicine — d&a has grown at a -3.4% compound annual growth rate (CAGR), from $4.03B to $3.76B.
- What does innovative medicine — d&a mean?
- The non-cash cost of using up physical assets and intangible intellectual property within the Innovative Medicine business.